[1] Drlica K.The mutant selection concentration and antimicrobial resistance[J]. J Antimicrob Chemotherk, 2003;52:11-17. [2] Zhao X, Drlica K.Restricting the selection of antibiotic-resistant mutant bacteria:measurement and potential use of the mutant selection window[J]. J Infect Dis, 2002;185:561-565. [3] Blondeau JM, Zhao X, Hansen J, et al. Mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae[J]. Antimicrob Agents Chemother, 2001;45:433-438. [4] 张莉, 李家泰, 吕媛, 等.左氧氟沙星注射液及口服片剂在健康人体内的药动学研究[J]. 中国药学杂志, 2001;36:834-837. [5] 胡瑾瑜, 施耀国, 张菁, 等.万古霉素在健康老年人和年轻人的药代动力学[J]. 中国抗感染化疗杂志, 2003;3:138-142. [6] 王建, 侯艳宁, 刘会臣, 等.国产利福平胶囊的人体相对生物度[J]. 中国药房, 1998;9:224-225. [7] 谢林, 刘晓东, 王大为.注射用阿奇霉素的生物利用度研究[J]. 江苏药学与临床研究, 2004;12:12-14. [8] Burke J,WarginW, Sherertz R, et al. Pharmacoki-netics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function[J]. J Pharmacokinet Biopharm,1982;10:601-614. [9] Bates R, Nahata M, Jones J, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis[J]. Chest, 1997;112:1208-1213. [10] 10 Smith HJ, Nichol KA, Hoban DJ, et al. Stretching the mutant prevention concentration (MPC) beyond its limits[J]. Antimicrob Chemother, 2003;51:1323-1325. [11] Zhao X.Clarification of MPC and the mutant selection window concept[J]. Antimicrob Chemother, 2003;52:731. [12] Lu T, Zhao X, Li X, et al. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of My cobacterium smegmatis and Staphy lococcus aureus[J]. Antimicrob Chemother, 2003;52:61-64. |